Immunomedics, Inc.

Monoclonal antibody-focused company reports loss of $0.16 per share

Published in Medicine and Law Weekly, December 16th, 2005

Immunomedics, Inc., (IMMU) reported revenues of $0.4 million and a net loss of $8.5 million, or $0.16 per share, for the first quarter of fiscal year 2006, which ended September 30, 2005.

This compares to revenues of $1.1 million and a net loss of $4.2 million, or $0.08 per share, for the same period last year. Cash used to fund operations for the first 3 months was $8.9 million as compared to $5.0 million for the same period last year. The increased use of cash of $3.9 million is due primarily to the ALLEVIATE trials evaluating epratuzumab in patients with lupus, and lower sales revenue from diagnostic imaging products.

At September 30, 2005, the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medicine and Law Weekly

Source: Medicine and Law Weekly (2005-12-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry